139 related articles for article (PubMed ID: 37477404)
1. BRAF-MEK Inhibition Is Effective in BRAFV600E-Mutant Papillary Craniopharyngioma.
Cancer Discov; 2023 Sep; 13(9):1960. PubMed ID: 37477404
[TBL] [Abstract][Full Text] [Related]
2. BRAF plus MEK inhibition effective in papillary craniopharyngioma.
Sidaway P
Nat Rev Clin Oncol; 2023 Oct; 20(10):661. PubMed ID: 37491596
[No Abstract] [Full Text] [Related]
3. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
Roque A; Odia Y
CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
[TBL] [Abstract][Full Text] [Related]
4. Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma.
Khaddour K; Chicoine MR; Huang J; Dahiya S; Ansstas G
J Natl Compr Canc Netw; 2020 Dec; 18(12):1590-1595. PubMed ID: 33285519
[TBL] [Abstract][Full Text] [Related]
5. Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review.
Yu N; Raslan OA; Lee HS; Theeler BJ; Raafat TA; Fragoso R; Shahlaie K; Aboud O
CNS Oncol; 2024 Jan; 13(1):CNS106. PubMed ID: 38348829
[TBL] [Abstract][Full Text] [Related]
6. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.
Rostami E; Witt Nyström P; Libard S; Wikström J; Casar-Borota O; Gudjonsson O
Acta Neurochir (Wien); 2017 Nov; 159(11):2217-2221. PubMed ID: 28918496
[TBL] [Abstract][Full Text] [Related]
7. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma.
Wu ZP; Wang YL; Wang LC; Liu ZY; Fan RR; Zan X; Liang RC; Yang JL; Zhou LX; Xu JG
World Neurosurg; 2023 Dec; 180():e117-e126. PubMed ID: 37683921
[TBL] [Abstract][Full Text] [Related]
9. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
Brastianos PK; Twohy E; Geyer S; Gerstner ER; Kaufmann TJ; Tabrizi S; Kabat B; Thierauf J; Ruff MW; Bota DA; Reardon DA; Cohen AL; De La Fuente MI; Lesser GJ; Campian J; Agarwalla PK; Kumthekar P; Mann B; Vora S; Knopp M; Iafrate AJ; Curry WT; Cahill DP; Shih HA; Brown PD; Santagata S; Barker FG; Galanis E
N Engl J Med; 2023 Jul; 389(2):118-126. PubMed ID: 37437144
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm.
Calvanese F; Jacquesson T; Manet R; Vasiljevic A; Lasolle H; Ducray F; Raverot G; Jouanneau E
Front Endocrinol (Lausanne); 2022; 13():882381. PubMed ID: 35757402
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
Schmitt AM; Dumas L; Larkin J
Expert Rev Anticancer Ther; 2022 Jan; 22(1):17-25. PubMed ID: 34904502
[TBL] [Abstract][Full Text] [Related]
12. Effect of BRAF/MEK Inhibition on Epithelioid Glioblastoma with BRAFV600E Mutation: a Case Report and Review of the Literature.
Li Y; Yang S; Hao C; Chen J; Li S; Kang Z; Kang X; Zhang H; Li W
Clin Lab; 2020 Aug; 66(8):. PubMed ID: 32776753
[TBL] [Abstract][Full Text] [Related]
13. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
Corcoran RB; Rothenberg SM; Hata AN; Faber AC; Piris A; Nazarian RM; Brown RD; Godfrey JT; Winokur D; Walsh J; Mino-Kenudson M; Maheswaran S; Settleman J; Wargo JA; Flaherty KT; Haber DA; Engelman JA
Sci Transl Med; 2013 Jul; 5(196):196ra98. PubMed ID: 23903755
[TBL] [Abstract][Full Text] [Related]
14. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
Leboeuf R; Baumgartner JE; Benezra M; Malaguarnera R; Solit D; Pratilas CA; Rosen N; Knauf JA; Fagin JA
J Clin Endocrinol Metab; 2008 Jun; 93(6):2194-201. PubMed ID: 18381570
[TBL] [Abstract][Full Text] [Related]
15. BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series.
Butt SU; Mejias A; Morelli C; Torga G; Happe M; Patrikidou A; Arkenau HT
Cancer Chemother Pharmacol; 2021 Mar; 87(3):437-441. PubMed ID: 33537843
[TBL] [Abstract][Full Text] [Related]
16. Optic tract edema in craniopharyngioma as a predictor of BRAFV600E mutation presence.
Taguchi A; Kinoshita Y; Kojima M; Amatya VJ; Tominaga A; Takeshima Y; Arita K; Hiyama E; Yamasaki F; Horie N
Jpn J Clin Oncol; 2023 Apr; 53(5):378-385. PubMed ID: 36702745
[TBL] [Abstract][Full Text] [Related]
17. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Cheng L; Jin Y; Liu M; Ruan M; Chen L
Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies in the medical management of craniopharyngioma.
Iglesias P
Pituitary; 2022 Jun; 25(3):383-392. PubMed ID: 35301645
[TBL] [Abstract][Full Text] [Related]
19. A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.
Fujio S; Juratli TA; Arita K; Hirano H; Nagano Y; Takajo T; Yoshimoto K; Bihun IV; Kaplan AB; Nayyar N; Fink AL; Bertalan MS; Tummala SS; Curry WT; Jones PS; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
Neurosurgery; 2019 Aug; 85(2):204-210. PubMed ID: 30481321
[TBL] [Abstract][Full Text] [Related]
20. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
